Icon Plc is a leading global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in offering a comprehensive range of services that encompass a wide array of phases in the drug development process, from early-stage research and clinical trials to regulatory submissions and post-market support. With a focus on advancing healthcare innovations, Icon collaborates closely with its clients to optimize their product development strategies, improve operational efficiency, and accelerate the path to market for new therapeutic products. Their expertise encompasses various therapeutic areas, providing tailored solutions that address the specific needs of each client. Read More
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ICON plc (NASDAQ: ICLR) resulting from allegations that ICON plc may have issued materially misleading business information to the investing public.
Date: February 12, 2026 Introduction ICON plc (NASDAQ: ICLR) currently finds itself at a pivotal and precarious crossroads. As the world’s second-largest Clinical Research Organization (CRO), the Dublin-headquartered giant has long been the backbone of global drug development, orchestrating the complex trials that bring life-saving therapies to market. However, as of February 2026, the company [...]
ICON plc, (NASDAQ: ICLR) today announced that it intends to release its fourth quarter and full year 2025 earnings results on or prior to April 30, 2026. The Company also announced an ongoing internal investigation initiated by the Audit Committee of the Board of Directors in late October 2025 into certain of the Company’s accounting practices and controls, following concerns reported to the Audit Committee through Company management. Outside legal counsel is conducting the investigation with the support of forensic and technical accounting firms.
ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois.
In the complex ecosystem of modern medicine, few companies carry as much institutional weight—or stir as much controversy—as Charles River Laboratories International, Inc. (NYSE: CRL). As of December 23, 2025, Charles River stands as the indispensable backbone of the global pharmaceutical industry. It is a company that has, remarkably, participated in the development of over [...]
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC) and the Middle East.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines.
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 am GMT.
ICON PLC's Q3 2025 results show a mixed quarter with a slight revenue beat but an EPS miss. Shares fell as the company lowered its full-year guidance due to sector headwinds.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the third quarter ended September 30, 2025.
ICON PLC (ICLR) presents a strong value investing case with attractive P/E ratios, solid profitability, and stable financial health, suggesting potential undervaluation.
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 23, 2025 at 8:00am ET.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON’s Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board as a non-executive director to facilitate a smooth transition.
